UroGen Pharma Ltd. (Nasdaq: URGN), to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, June 07, 2017 (GLOBE NEWSWIRE) —

What: 
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Arie Belldegrun, MD, UroGen’s Chairman, and Ron Bentsur, UroGen’s Chief Executive Officer, will ring the Opening Bell. 

Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:
Thursday, June 8, 2017 – 9:15 a.m. to 9:30 a.m. ET        

UroGen Contact:
Steve Klass
Burns McClellan, Inc.
(212) 213-0006
[email protected]

Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About UroGen Pharma Ltd.
UroGen Pharma (NASDAQ:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology.  The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs.  UroGen Pharma’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option.  UroGen Pharma’s lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer.  UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com.

-NDAQA-

Leave a Reply

Your email address will not be published. Required fields are marked *